These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37942683)

  • 1. Asymmetry of thalamic hypometabolism on FDG-PET/CT in neurofibromatosis type 1: Association with peripheral tumor burden.
    Özden C; Mautner VF; Farschtschi S; Molwitz I; Ristow I; Bannas P; Well L; Klutmann S; Adam G; Apostolova I; Buchert R
    J Neuroimaging; 2024; 34(1):138-144. PubMed ID: 37942683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.
    Salamon J; Papp L; Tóth Z; Laqmani A; Apostolova I; Adam G; Mautner VF; Derlin T
    PLoS One; 2015; 10(12):e0143305. PubMed ID: 26625155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
    Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Ahlawat S; Blakeley JO; Rodriguez FJ; Fayad LM
    Neurology; 2019 Sep; 93(11):e1076-e1084. PubMed ID: 31395668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
    Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced thalamic 18F-flurodeoxyglucose retention in adults with neurofibromatosis type 1.
    Buchert R; von Borczyskowski D; Wilke F; Gronowsky M; Friedrich RE; Brenner W; Mester J; Clausen M; Mautner VF
    Nucl Med Commun; 2008 Jan; 29(1):17-26. PubMed ID: 18049093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?
    Berzaczy D; Mayerhoefer ME; Azizi AA; Haug AR; Senn D; Beitzke D; Weber M; Traub-Weidinger T
    PLoS One; 2017; 12(12):e0189093. PubMed ID: 29206885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral glucose metabolism in adults with neurofibromatosis type 1.
    Apostolova I; Derlin T; Salamon J; Amthauer H; Granström S; Brenner W; Mautner VF; Buchert R
    Brain Res; 2015 Nov; 1625():97-101. PubMed ID: 26335059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
    Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
    Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
    PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalamic abnormalities in children with continuous spike-wave during slow-wave sleep: An F-18-fluorodeoxyglucose positron emission tomography perspective.
    Agarwal R; Kumar A; Tiwari VN; Chugani H
    Epilepsia; 2016 Feb; 57(2):263-71. PubMed ID: 26697846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.